Ibrutinib: A narrative drug review
Ibrutinib is an oral, irreversible covalent inhibitor of the Bruton tyrosine kinase, that plays a major role in B-cell differentiation, proliferation, migration, survival, and apoptosis. It has been found to be active against a number of B-cell malignancies. Ibrutinib has shifted the treatment strat...
Main Authors: | Pritesh Naresh Munot, Sumeet Mirgh, Nikita Mehra, Bhausaheb P Bagal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Cancer Research, Statistics, and Treatment |
Subjects: | |
Online Access: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2020;volume=3;issue=4;spage=767;epage=784;aulast=Munot |
Similar Items
-
Bing‐Neel syndrome
by: Katelynn Davis, et al.
Published: (2022-11-01) -
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
by: C. I. Edvard Smith, et al.
Published: (2021-06-01) -
Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01) -
Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia
by: Haya Jamali, et al.
Published: (2023-05-01) -
Waldenström macroglobulinemia: biology, genetics, and therapy
by: Paludo J, et al.
Published: (2016-07-01)